Track

Case Reports

Abstract

Keratoacanthomas are squamoproliferative lesions that are associated with different clinical presentations. Solitary tumors may grow rapidly and then involute, or progress to giant keratoacanthomas. Genetic syndromes such as Muir-Torre, xeroderma pigmentosum, Ferguson-Smith, and Grzybowski may predispose patients to the development of multiple keratoacanthomas. Additionally, medications such as pembrolizumab, leflunomide, vismodegib, transforming growth factor beta inhibitors, sorafenib, and other BRAF inhibitors have been shown to precipitate keratoacanthomas. Generalized eruptive keratoacanthomas may be difficult to treat but tend to have a benign clinical course. Eruptive squamous atypia (ESA) has been suggested as another name for this entity in order to highlight differences from conventional squamous cell carcinoma. We present a patient undergoing chemotherapy treatment for bladder cancer who developed generalized eruptive keratoacanthomas in order to highlight clinical and histologic features of this phenomenon.